Pr Alexander M. Eggermont of Institut Gustav Roussy in Paris and study coordinator of EORTC trial 18071, presented the initial efficacy and safety results from that phase III trial at ASCO 2014 in Chicago. This trial showed that adjuvant therapy with ipilimumab (Yervoy) for patients with high-risk stage III melanoma significantly improved recurrence-free survival.
Dr. Cora N. Sternberg of the San Camillo and Forlanini Hospitals in Rome and study coordinator of EORTC trial 30994, presented the long term results of that trial at ASCO 2014 in Chicago. The results lend new support to use of immediate cisplatin-based chemotherapy following surgical resection.
Head and neck cancer is very common, and its incidence is rising. In 2008 in Europe the estimated number of cases was 40.4 thousand for larynx, 44.7 thousand for esophagus, and 91.9 thousand for oral cavity and pharynx (Ferlay et al. 2010). In 2012, those numbers were 39.9 thousand for larynx, 45.9 thousand for esophagus, and 99.6 thousand for oral cavity and pharynx (Ferlay et al. 2013).
Le cancer est la deuxième cause de mortalité en Europe, après les maladies cardio-vasculaires. Chaque année, près de 3 500 000 nouveaux cas de cancer sont diagnostiqués dans les pays de l’Union européenne. Face à ce nombre substantiel, l’investissement dans la recherche clinique en cancérologie demeure essentiel. C’est dans cet esprit que l’Organisation européenne pour la Recherche et le Traitement du Cancer (EORTC) fut fondée dès les années ’60 afin de proposer aux patients les meilleurs traitements.
The second edition of SPECTAforum met its objectives with representation of most of the stakeholders. With SPECTAcolor, the first platform, now rapidly reaching over 200 patients, SPECTA, an innovative approach to efficient access to molecular target-based clinical trials, has demonstrated international feasibility. Routes for stakeholders to join SPECTA are now being launched. Additional disease-oriented platforms are actively being developed and will be launched soon.
Although Richard Sylvester officially retired in May 2012 after nearly 37 years at EORTC Headquarters, most of which were spent as the head of the Statistics Department, his scientific activities still keep him very busy.
Richard still works one day a week at EORTC Headquarters pursuing his main research interest, non-muscle invasive bladder cancer (NMIBC). The EORTC database of bladder cancer studies provides a valuable source of data for his research on prognostic factors and more specifically the prognostic and predictive effect of age.
The EORTC will present nine abstracts at the ASCO 2014 Annual Meeting which will be held 30 May - 03 June 2014 in Chicago, Illinois. Four abstracts will be presented in Oral Abstract Sessions, one in a Poster Highlights Session, and another four in General Poster Sessions.
Abstract # 4500
Monday, 02 June, 9:45 – 9:57, E Hall D1
In the European Union there were an estimated 36,900 new cases of thyroid cancer and 3600 deaths in 2012. Although thyroid cancer is rare, it is the most common endocrine cancer. Among thyroid tumors, the vast majority are differentiated carcinomas (approximately 90%), and medullary cancers make up between 5 and 10%.
In an article published in The Lancet Oncology, an NCI (US National Cancer Institute), NCRI (UK National Cancer Research Institute), and EORTC (European Organisation for Research and Treatment of Cancer) working group outline a practical risk-management approach for effective integration of biomarkers into cancer clinical trials.
Approximately half of all patients diagnosed with non-small cell lung cancer are 70 years of age or older, yet despite this high percentage, these elderly patients are not well represented in clinical trials. Therefore, the paucity of clinical data has made it difficult to reach evidence based clinical recommendations.
